START CARE ASTHMA STUDY
Do you know someone 5-15 years old, with asthma, who may be open to participating in a world-leading study?
The Medical Research Institute of New Zealand (MRINZ)are currently running a groundbreaking asthma trial for tamariki. The START CARE Asthma Study compares two different inhalers to find out which one is better at preventing asthma attacks in children. This potentially world-changing research, by Aotearoa New Zealand’s leading independent medical research institute, aims to help kids everywhere, particularly tamariki here in Aotearoa, which has some of the worst asthma rates in the world.
Watch the little video below to find out more, or head straight to the START CARE STUDY summary to get all the details.
The MRINZ are currently running the START CARE Study, comparing two different inhalers to find out which one is better at preventing asthma attacks in kids. ...
SOCIAL / SHORT FORM POSTING COPY
Does your child have asthma? Perhaps they might be interested in joining a world-leading study led by the @MedicalResearchInstituteofNewZealand.
The START CARE Study is looking for children aged 5-15 to participate in research comparing two different inhalers to determine which one is more effective at preventing asthma attacks in kids. By participating in this study, your child will contribute to a groundbreaking study that could change how we manage childhood asthma worldwide.
Watch the little video [POST VIDEO https://youtu.be/dbYNYUm_SSw] or click the link below for more details on how your child could be part of this important study. Let's work together to improve asthma care for our tamariki. FIND OUT MORE https://tinyurl.com/bdhrnjvx
#MRINZ #STARTCAREStudy #AsthmaResearch #AsthmaPrevention #KidsHealth #JoinTheStudy
FURTHER MRINZ START CARE ASTHMA STUDY BACKGROUND
One in seven children in Aotearoa, New Zealand, has asthma, which accounts for more than 10% of all GP consultations for children, 325,000 asthma-related prescriptions, and 3,000 hospital admissions annually.
Most children in New Zealand rely on short-acting relievers like Ventolin or Respigen to treat their asthma. While these inhalers quickly relieve symptoms they do not address the underlying airway inflammation. The Medical Research Institute of New Zealand (MRINZ) has made a significant impact on global asthma treatment by demonstrating that in adults, using a 2-in-1 Symbicort inhaler can reduce the risk of a severe asthma attack by up to one-half compared to using a salbutamol reliever inhaler.
A 2-in-1 inhaler containing both a steroid and a long-acting reliever treats airway inflammation and relieves symptoms with each use. The current START CARE study will determine if the benefits of Symbicort reliever seen in adults also apply to children.
If the results of the START CARE study are comparable, then the findings have the potential to change practice and markedly reduce the burden of childhood asthma in Aotearoa New Zealand and globally. FIND OUT MOREhttps://www.mrinz.ac.nz/currently-recruiting/startcare